创新公司和Eli Lilly公司启动了全球肿瘤学和免疫学合作,前期350M美元,最高达8.5B美元,具有里程碑意义。 Innovent and Eli Lilly launch global oncology and immunology collaboration with $350M upfront and up to $8.5B in milestones.

2026年2月8日,创新生物学和Eli Lilly & Company宣布开展全球合作,开发新的肿瘤学和免疫学治疗,这是它们第七个伙伴关系。 Innovent Biologics and Eli Lilly & Company announced a global collaboration on February 8, 2026, to develop new oncology and immunology treatments, their seventh partnership. 创新将引导中国的早期发展,而Lilly则获得专有权利,在全世界大中国以外发展候选人并使其商业化。 Innovent will lead early development in China, while Lilly gains exclusive rights to develop and commercialize candidates worldwide outside Greater China. Innovent 可获得3.5亿美元的预付款，以及可能高达85亿美元的里程碑付款，以及大中华区以外的版税。 Innovent receives a $350 million upfront payment and potential up to $8.5 billion in milestone payments, plus royalties outside Greater China. 这笔交易利用创新者抗体平台和莉莉的全球影响力,支持创新者提供负担得起的生物制药的任务。 The deal leverages Innovent’s antibody platforms and Lilly’s global reach, supporting Innovent’s mission to deliver affordable biopharmaceuticals.